Adults with advanced multiple myeloma and renal insufficiency treated with idecabtagene vicleucel achieved similar outcomes as those with normal renal function, according to retrospective study results.
A single dose of the chimeric antigen receptor T-cell therapy presents no additional risk for treatment-related toxicities among patients with renal insufficiency, findings presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR showed.
“Patients with multiple myeloma and renal impairment … should not be denied this therapy,” Surbhi
